# A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Study · id `cardio:ct-nct02205528` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02205528](<https://clinicaltrials.gov/study/NCT02205528>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02205528

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

## Technical summary

Registry record NCT02205528. Randomized; double masking; primary purpose treatment. Start 2014-08-18 (actual); primary completion 2015-09-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 108 participants (enrolled count; ClinicalTrials.gov record NCT02205528, source copy `cardio:ctgov-nct02205528-2020-07-21`, retrieved 2026-10-26)
- Started: 2014-08-18 (actual) (ClinicalTrials.gov record NCT02205528, source copy `cardio:ctgov-nct02205528-2020-07-21`, retrieved 2026-10-26)
- Primary completion: 2015-09-15 (actual) (ClinicalTrials.gov record NCT02205528, source copy `cardio:ctgov-nct02205528-2020-07-21`, retrieved 2026-10-26)
- Completion: 2015-09-15 (actual) (ClinicalTrials.gov record NCT02205528, source copy `cardio:ctgov-nct02205528-2020-07-21`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02205528, source copy `cardio:ctgov-nct02205528-2020-07-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02205528-2020-07-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
- Condition: Diabetes
- Condition: Diabetes Mellitus Type 2
- Intervention (Drug): Liraglutide
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo
- Intervention (Drug): NNC0090-2746
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes (`cardio:pubmed-28768173`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2d38d2167d644acf8169ec36961e4be77ce71556b57a1e1a153245da7ac8fad4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
